Author:
Akiyama Shintaro,Yamada Akihiro,Micic Dejan,Sakuraba Atsushi
Reference74 articles.
1. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis;Gordon;J Invest Dermatol,2012
2. Briakinumab for treatment of Crohn's disease: results of a randomized trial;Panaccione;Inflamm Bowel Dis,2015
3. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2);Papp;Lancet,2008
4. Ustekinumab induction and maintenance therapy in refractory Crohn's disease;Sandborn;N Engl J Med,2012
5. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials;Reich;Lancet,2017
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献